Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016

Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016
Published Jun 30, 2016
62 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016, provides in depth analysis on Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2)
- The report reviews Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive adva

  
Source:
Document ID
GMDHC0233TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Overview71
Therapeutics Development84
  Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Stage of Development81
  Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Therapy Area91
  Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Indication102
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Companies142
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Products under Development by Universities/Institutes162
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Companies Involved in Therapeutics Development248
  Array BioPharma Inc.241
  Bristol-Myers Squibb Company251
  Genentech, Inc.261
  Nimbus Therapeutics, LLC271
  Portola Pharmaceuticals, Inc.281
  Sareum Holdings Plc291
  Takeda Pharmaceutical Company Limited301
  Theravance Biopharma, Inc.311
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Drug Profiles3215
  ARRY-111 Drug Profile321
  cerdulatinib Drug Profile333
  SAR-20347 Drug Profile362
  SART-1 Drug Profile381
  SART-29 Drug Profile391
  SART-33 Drug Profile401
  Small Molecule to Inhibit TYK2 for Immunology Drug Profile411
  Small Molecule to Inhibit TYK2 for Psoriasis and IBD Drug Profile421
  Small Molecules to Inhibit TYK2 Drug Profile431
  Small Molecules to Inhibit Tyk2 for Inflammation and Oncology Drug Profile441
  Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases Drug Profile451
  TD-1473 Drug Profile461
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Discontinued Products471
Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) Featured News &Press Releases4813
  Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor481
  Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings491
  Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016501
  Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor501
  Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor511
  Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor521
  Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition531
  Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs541
  Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor551
  Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK551
  May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib561
  May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting571
  Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme581
  Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting591
  Oct 01, 2014: Sareum Holdings Promising Step in Psoriasis Drug Development592
Appendix612
  Methodology611
  Coverage611
  Secondary Research611
  Primary Research611
  Expert Panel Validation611
  Contact Us611
  Disclaimer621

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Non-Receptor-Tyrosine-Protein-Kinase-TYK2-Tyrosine-Kinase-2-or-EC-2-7-10-2-Pipeline-Review-H1-2016-2088-16116>
  
APA:
Global Markets Direct - Market Research. (2016). Non-Receptor Tyrosine-Protein Kinase TYK2 (Tyrosine Kinase 2 or EC 2.7.10.2) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Non-Receptor-Tyrosine-Protein-Kinase-TYK2-Tyrosine-Kinase-2-or-EC-2-7-10-2-Pipeline-Review-H1-2016-2088-16116>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.